Rutgers Receives FDA Approval for Cancer Therapy Clinical Trials

Actinobac Biomed, a company founded by Rutgers School of Dental Medicine researcher Scott Kachlany, PhD, has received U.S. Food and Drug Administration approval to begin a Phase I clinical trial in patients who have relapsed or refractory leukemia of lymphoma, according to the college.

Clinical trials for the drug, leukothera, will begin with 24 patients. This experimental drug kills cancer cells, but does not compromise the immune system. Learn more at newswise.com.